Log In
BCIQ
Print this Print this
 

Fluenz Tetra, FluMist Quadrivalent (MEDI-3250)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionIntranasal live attenuated influenza vaccine (LAIV) containing 2 strains of type A (H1N1 and H3N2) and 2 strains of type B (1 each from Yamagata and Victoria lineages)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationInfluenza virus
Indication DetailsPrevent seasonal influenza in children ages 24 months to less than 18 years; Prevent seasonal influenza in healthy children ages 2-8 years who have no contraindications or precautions; Prevent seasonal influenza in people ages 2 to 49 years old; Treat influenza virus
Regulatory Designation
PartnerDaiichi Sankyo Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/02/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today